structure-based design fusion glycoprotein vaccine respiratory syncytial virus 
respiratory syncytial virus rsv leading cause hospitalization children years age sought engineer viral antigen provides greater protection currently available vaccines focused antigenic site empty set metastable site specific prefusion state rsv fusion f glycoprotein site targeted extremely potent rsv-neutralizing antibodies structure-based design yielded stabilized versions rsv f maintained antigenic site empty set exposed extremes ph osmolality temperature six rsv f crystal structures provided atomic-level data introduced cysteine residues filled hydrophobic cavities improved stability immunization site empty set-stabilized variants rsv f mice macaques elicited levels rsv-specific neutralizing activity many times protective threshold 
